-

McKesson’s Board of Directors Elects Deborah Dunsire as New Director

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that the McKesson board of directors has elected Dr. Deborah Dunsire as a director and member of the Compensation and Talent Committee and Finance Committee, effective June 3, 2024.

“We’re pleased to welcome Deborah to the McKesson board,” said Donald Knauss, McKesson’s independent board chair. “She is a highly respected healthcare industry leader with a proven track record of leading large, complex organizations as both a CEO and a board member. Her unique perspective, clinical background and expertise within the pharmaceutical and oncology arenas will add great value to McKesson and its purpose of Advancing Health Outcomes for All®.”

Dr. Dunsire joins the board with over 30 years of experience leading large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Most recently, she retired from her role as president and chief executive officer of H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases. Prior to that, she held executive leadership roles for several pharmaceutical companies including XTuit Pharmaceuticals, FORUM Pharmaceuticals, Millennium: The Takeda Oncology Company and Millennium Pharmaceuticals. Dr. Dunsire started her career as a primary care physician in Johannesburg, South Africa.

Dr. Dunsire currently serves on the boards of directors of Syros Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. She received her medical degree from the University of Witwatersrand in Johannesburg, South Africa.

Board members Linda Mantia, who is no longer independent, and Susan Salka, who has served on the board for almost ten years, will not be standing for re-election at the 2024 Annual Meeting of Shareholders. Upon the election of all proposed director nominees at the Annual Meeting, the size of the board will be reduced to 11 members, 10 of whom are independent.

Mr. Knauss stated, “We want to thank Linda and Susan for their leadership and dedicated service to the McKesson board and our shareholders. We appreciate the significant contributions they have made over the years, including their service as committee chairs, and wish them all the best in the future.”

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

Contacts

Rachel Rodriguez, 469-260-0556 (Investors)
Rachel.Rodriguez@McKesson.com
Media Relations
MediaRelations@McKesson.com

McKesson Corporation

NYSE:MCK

Release Versions

Contacts

Rachel Rodriguez, 469-260-0556 (Investors)
Rachel.Rodriguez@McKesson.com
Media Relations
MediaRelations@McKesson.com

More News From McKesson Corporation

McKesson to Host Investor Day on September 23, 2025

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced it will host an Investor Day on Tuesday, September 23, 2025, in New York City. The event will feature presentations by McKesson’s leadership team followed by a Q&A session with chief executive officer Brian Tyler and chief financial officer Britt Vitalone. Management will provide an update on the company’s strategic priorities, growth strategies, and business outlook. A live webcast of the event and replay, along wit...

McKesson Corporation Completes Acquisition of Core Ventures

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS). The acquisition advances community-based oncology care and enables McKesson to continue to accelerate clinical development, improve patient outc...

McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and arc...
Back to Newsroom